Investigational Treatment for Alzheimer Disease Reports Positive Topline Clinical Data
The investigational therapy BIIB080/IONIS-MAPTRx (Biogen Inc and Ionis Pharmaceuticals) met its number one goal of safety and tolerability in sufferers with slight Alzheimer sickness in a section 1b placebo-managed, more than one ascending dose clinical study, in keeping with a press launch from Biogen. The examine further proven robust time and dose-established decreasing of tau protein in cerebrospinal fluid (CSF) over the route of the 3-month remedy length. These discounts have been sustained over the 6-month post-treatment length.